BioAscent is pleased to announce the acquisition of a high-value chemogenomic compound library which significantly enhances its capabilities in early-stage drug discovery. The library comprises over 1,600 diverse, highly selective and well-annotated pharmacologically active probe molecules thereby making it a powerful tool for phenotypic screening and mechanism of action studies. Classes of compounds in the library include:

• Kinase inhibitors

• GPCR ligands (agonists, antagonists, allosteric modulators)

• Target-specific epigenetic modifiers

• And more, all with extensive pharmacological annotations.

This expanded offering complements BioAscent’s existing compound libraries, which includes:

• 1,300-fragments, incorporating hundreds of bespoke, structurally unique fragments designed and synthesised by BioAscent’s expert chemists. 

• Our 100,000-compound diversity library, rigorously analysed to run full scale HTS or to enable cost-effective pilot and iterative screening strategies, with a proven track record of hit-finding against challenging targets.

All BioAscent’s compound libraries are stored and managed in our industry-leading compound management facility, ensuring the highest standards of quality, integrity, and logistical efficiency. This enables seamless integration of screening compounds into client projects while maximising reliability and reproducibility in drug discovery efforts.

These libraries are available without intellectual property encumbrances, allowing BioAscent’s clients to fully leverage these assets in their research programmes. By providing access to these high-quality, curated collections, BioAscent continues to support innovative drug discovery efforts, enabling researchers to rapidly identify novel mechanisms of action and advance their therapeutic projects with greater confidence.

Click here to learn more about BioAscent's in-house diversity and fragments library.